William Blair reiterated their neutral rating on shares of Acer Therapeutics (NASDAQ:ACER) in a research note issued to investors on Friday morning, AnalystRatings.com reports.
ACER has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Acer Therapeutics from a sell rating to a hold rating in a research report on Friday, May 17th. BidaskClub upgraded shares of Acer Therapeutics from a sell rating to a hold rating in a research report on Saturday, April 13th. ValuEngine upgraded shares of Acer Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. Needham & Company LLC cut shares of Acer Therapeutics from a buy rating to a hold rating in a research report on Tuesday, June 25th. Finally, Raymond James cut shares of Acer Therapeutics from an outperform rating to a market perform rating in a research report on Tuesday, June 25th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Acer Therapeutics currently has a consensus rating of Hold and a consensus target price of $30.33.
Shares of Acer Therapeutics stock opened at $2.55 on Friday. Acer Therapeutics has a 52 week low of $2.49 and a 52 week high of $34.10. The company’s fifty day simple moving average is $5.60. The company has a market cap of $25.72 million, a PE ratio of -1.02 and a beta of 1.54.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wedbush Securities Inc. acquired a new position in Acer Therapeutics in the 2nd quarter worth $94,000. SG Americas Securities LLC acquired a new position in Acer Therapeutics in the 1st quarter worth $101,000. Laurion Capital Management LP acquired a new position in Acer Therapeutics in the 1st quarter worth $253,000. Tibra Equities Europe Ltd acquired a new position in Acer Therapeutics in the 1st quarter worth $297,000. Finally, Northern Trust Corp boosted its stake in Acer Therapeutics by 5.7% in the 4th quarter. Northern Trust Corp now owns 33,572 shares of the biopharmaceutical company’s stock worth $676,000 after purchasing an additional 1,797 shares during the period. 31.07% of the stock is owned by hedge funds and other institutional investors.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Recommended Story: How Do Mutual Funds Work?
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.